Merck (NYSE:MRK) and IAVI announced today that they are collaborating to develop an investigational vaccine against SARS-CoV-2 for preventing COVID-19.
The vaccine candidate is slated to use the recombinant vesicular stomatitis virus (rVSV) technology used as the basis for Merck’s Ervebo Ebola Zaire virus vaccine, which was the first such vaccine to be approved for use in humans, according to a news release. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Dept. of Health and Human Services, to provide funding for the collaboration.
Get the full story at our sister site, Drug Discovery & Development.